Our verdict is Likely benign. Variant got -2 ACMG points: 2P and 4B. PM2BP4_Strong
The NM_001101669.3(INPP4B):c.2205A>C(p.Glu735Asp) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a benign outcome for this variant. 14/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).
INPP4B (HGNC:6075): (inositol polyphosphate-4-phosphatase type II B) INPP4B encodes the inositol polyphosphate 4-phosphatase type II, one of the enzymes involved in phosphatidylinositol signaling pathways. This enzyme removes the phosphate group at position 4 of the inositol ring from inositol 3,4-bisphosphate. There is limited data to suggest that the human type II enzyme is subject to alternative splicing, as has been established for the type I enzyme. [provided by RefSeq, Jul 2008]
Review Status: criteria provided, single submitter
Collection Method: clinical testing
The c.2205A>C (p.E735D) alteration is located in exon 23 (coding exon 19) of the INPP4B gene. This alteration results from a A to C substitution at nucleotide position 2205, causing the glutamic acid (E) at amino acid position 735 to be replaced by an aspartic acid (D). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. -
Loss of methylation at K734 (P = 0.085);Loss of methylation at K734 (P = 0.085);Loss of methylation at K734 (P = 0.085);Loss of methylation at K734 (P = 0.085);.;Loss of methylation at K734 (P = 0.085);.;